Inhibition of p38 pathway leads to OA-like changes in a rat animal model

Rheumatology

Volumn 51, Issue 5, 2012, Pages 813-823

  Prasadam, Indira ^a   Mao, Xinzhan ^a,b,c   Wang, Yanping ^a,c   Shi, Wei ^a   Crawford, Ross ^a,b   Xiao, Yin ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cartilage; Hypertrophy; MAPK p38 signalling pathway; Osteoarthritis; Subchondral bone

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COLLAGEN TYPE 10; COLLAGENASE 3; DIMETHYL SULFOXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEOGLYCAN; TRANSCRIPTION FACTOR RUNX;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL ISOLATION; CHONDROGENESIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MENISCECTOMY; NICK END LABELING; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; RAT;

ANIMALS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MALE; MAP KINASE SIGNALING SYSTEM; OSTEOARTHRITIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RATS; RATS, INBRED WKY;

EID: 84860249551     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker360     Document Type: Article

References (35)

1. Aigner T, Zien A, Gehrsitz A et al. Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum 2001;44:2777-89.
2. Sondergaard BC, Schultz N, Madsen SH et al. MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation-divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthr Cartilage 2010;18:279-88.
3. Ding L, Guo D, Homandberg GA. The cartilage chondrolytic mechanism of fibronectin fragments involves MAP kinases: comparison of three fragments and native fibronectin. Osteoarthr Cartilage 2008;16:1253-62.
4. Stanton LA, Beier F. Inhibition of p38 MAPK signaling in chondrocyte cultures results in enhanced osteogenic differentiation of perichondral cells. Exp Cell Res 2007;313: 146-55.
5. Tew SR, Hardingham TE. Regulation of SOX9 mRNA in human articular chondrocytes involving p38 MAPK activation and mRNA stabilization. J Biol Chem 2006;281: 39471-9.
6. Zhen X, Wei L, Wu Q et al. Mitogen-activated protein kinase p38 mediates regulation of chondrocyte differentiation by parathyroid hormone. J Biol Chem 2001;276:4879-85.
7. Prasadam I, van Gennip S, Friis T et al. ERK-1/2 and p38 in the regulation of hypertrophic changes of normal articular cartilage chondrocytes induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum 2010;62:1349-60.
8. Long DL, Loeser RF. p38g mitogen-activated protein kinase suppresses chondrocyte production of MMP-13 in response to catabolic stimulation. Osteoarthritis Cartilage 2010;18:1203-10.
9. Loeser RF, Erickson EA, Long DL. Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol 2008;20:581-6.
10. Joos H, Albrecht W, Laufer S et al. Influence of p38MAPK inhibition on IL-1b-stimulated human chondrocytes: a microarray approach. Int J Mol Med 2009;23:685-93.
11. Martel-Pelletier J, Mineau F, Jovanovic D et al. Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK). Arthritis Rheum 1999;42:2399-409.
12. Otero M, Lago R, Lago F et al. Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res Ther 2005;7:R581-91.
13. Boileau C, Pelletier JP, Tardif G et al. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann Rheum Dis 2005; 64:891-8.
14. Pan Q, Yu Y, Chen Q et al. Sox9, a key transcription factor of bone morphogenetic protein-2-induced chondrogenesis, is activated through BMP pathway and a CCAAT box in the proximal promoter. J Cell Physiol 2008;217:228-41.
15. Nash SP, Heuertz RM. Blockade of p38 map kinase inhibits complement-induced acute lung injury in a murine model. Int Immunopharmacol 2005;5:1870-80.
16. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67:909-16.
17. Liu S, Feng G, Wang GL et al. p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Eur J Pharmacol 2008;584:159-65.
18. Berzingi C, Chen F, Finkel MS. p38 MAP kinase inhibitor prevents diastolic dysfunction in rats following HIV gp120 injection in vivo. Cardiovasc Toxicol 2009;9:142-50.
19. Mankin HJ, Buckwalter JA. Articular cartilage structure, composition and function, 2nd edn. Rosemont, IL: American Academy of Orthopaedic Surgeons, 2000.
20. Mankin HJ, Dorfman H, Lippiello L et al. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37.
21. Prasadam I, Friis T, Shi W et al. Osteoarthritic cartilage chondrocytes alter subchondral bone osteoblast differentiation via MAPK signalling pathway involving ERK1/2. Bone 2010;46:226-35.
22. Chen F, Kan H, Hobbs G et al. p38 MAP kinase inhibitor reverses stress-induced myocardial dysfunction in vivo. J Appl Physiol 2009;106:1132-41.
23. Yin H, Zhang J, Lin H et al. p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia. Inflammation 2008;31:65-73.
24. Badger AM, Bradbeer JN, Votta B et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279: 1453-61.
25. Weerackody RP, Welsh DJ, Wadsworth RM et al. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol 2009;296:H1312-20.
26. Revesz L, Blum E, Di Padova FE et al. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg Med Chem Lett 2004;14:3595-9.
27. Li J, Zhao Z, Liu J et al. MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells through delicate interaction with TGF-beta1/Smads pathway. Cell Prolif 2010;43:333-43.
28. Zhang R, Murakami S, Coustry F et al. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc Natl Acad Sci USA 2006;103:365-70.
29. Greenblatt MB, Shim JH, Zou W et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 2010;120:2457-73.
30. Pullig O, Weseloh G, Ronneberger D et al. Chondrocyte differentiation in human osteoarthritis: expression of osteocalcin in normal and osteoarthritic cartilage and bone. Calcif Tissue Int 2000;67:230-40.
31. D'Angelo M, Yan Z, Nooreyazdan M et al. MMP-13 is induced during chondrocyte hypertrophy. J Cell Biochem 2000;77:678-93.
32. Namdari S, Wei L, Moore D et al. Reduced limb length and worsened osteoarthritis in adult mice after genetic inhibition of p38 MAP kinase activity in cartilage. Arthritis Rheum 2008;58:3520-9.
33. Dean JL, Sarsfield SJ, Tsounakou E et al. p38 Mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation. J Biol Chem 2003;278:39470-6.
34. Brown KK, Heitmeyer SA, Hookfin EB et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm 2008;5:22.
35. Xiao YQ, Malcolm K, Worthen GS et al. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem 2002;277:14884-93.